"On track for GaRP supplement partner"
PAC Partners Equity Research Report
Brisbane, Mar 19, 2019 AEST (ABN Newswire) - PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (
ASX:ANR) (ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.
Key Points
- ANR's in vitro gut testing was very successful (85+% efficacy) with gut disease (IBD* & IBS**) treatment.
- ANR is now on track for selection of global partner in 2HCY'19 for GaRP, and formal 2HCY'20 agreement.
- ANR will continue IBD mouse studies (complete Jul'19) and commence IBS human studies in 2HCY'19.
- This 100 patient clinical trial is more than what is required for "over the counter" sales. ANR is doing trials to attract a wider group of potential partners, and enable specific disease treatment claims.
- The nearest peer OTC drug is Bayer's Iberogast for indigestion and discomfort associated with IBD. Only two clinical trials with ~150 patients treated in each and 50 to 150 placebo were done in 2004 and 2007. Bayer paid a multiple of the Euro60m/a sales in 2013 for rights to Iberogast.
*IBD = Irritable Bowel Disease (5m global sufferers). *IBS = Irritable Bowel Syndrome (840m global sufferers).
To view the Research Report, please visit:
http://abnnewswire.net/lnk/Z238Z60W
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
